The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy
Open accessAbstract
Significance: Duchenne muscular dystrophy (DMD) is a rare and devastating muscle disease caused by mutations in the X-linked DMD gene (which encodes the dystrophin protein). Serum biomarkers hold significant potential as objective phenotypic measures of DMD disease state, as well as potential measures of pharmacological effects of and response to therapeutic interventions. Here we describe a proteomics approach to determine serum levels of 1,125 proteins in 93 DMD patients and 45 controls. The study identified 44 biomarkers that differed significantly between patients and controls. These data are being made available to DMD researchers and clinicians to accelerate the search for new diagnostic, prognostic, and therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 1×
“In statistical tests we account for multiple comparisons by reporting the FDR computed using the BH method (43)”
MethodCalcium's Role in Mechanotransduction during Muscle Development
Benavides Damm, T., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,502
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Self-citationBushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70271-6 · Cited by 2,053
Self-citationPrevalence of Muscular Dystrophies: A Systematic Literature Review
Theadom, A., Rodrigues, M., Roxburgh, R., Balalla, S., Higgins, C., Bhattacharjee, R., Jones, K., Krishnamurthi, R., & Feigin, V. (2014) · Neuroepidemiology · doi:10.1159/000369343 · Cited by 2,046
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867 · cited 2×
“However, verification and validation of MS-discovered serum biomarkers remain challenging (24).”
BackgroundAptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754
Self-citationA role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin
Ervasti, J., & Campbell, K. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.4.809 · Cited by 1,388
Loffredo, F. S., Steinhauser, M. L., Jay, S. M., Gannon, J., Pancoast, J. R., Yalamanchi, P., Sinha, M., Dall’Osso, C., Khong, D., Shadrach, J. L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.015 · Cited by 948 · cited 1×
“GDF-11 is of particular interest, given recent studies that have suggested that exogenous GDF-11 can reverse age-related cardiomyopathy (37) and skeletal muscle deterioration (38) in mice.”
BackgroundSelf-citationCirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60756-3 · Cited by 878
Eteplirsen for the treatment of Duchenne muscular dystrophy
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23982 · Cited by 817
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., Ekhart, P. F., Heuvelmans, N., Holling, T., Janson, A. A., Platenburg, G. J., Sipkens, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011367 · Cited by 678
Dystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655 · cited 1×
“Promising therapeutic approaches for DMD include restoring expression of the dystrophin gene via exon-skipping strategies (11–13), viral-based gene therapies (14, 15), and nonsense suppression/read-through strategies (16).”
BackgroundThe Clinical Plasma Proteome: A Survey of Clinical Assays for Proteins in Plasma and Serum
Anderson, N. L. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.126706 · Cited by 562
Glucocorticoid corticosteroids for Duchenne muscular dystrophy
Manzur, A., Kuntzer, T., Pike, M., & Swan, A. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub2 · Cited by 539
Rohloff, J. C., Gelinas, A. D., Jarvis, T. C., Ochsner, U. A., Schneider, D. J., Gold, L., & Janjic, N. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.49 · Cited by 533
Self-citationA systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy
Mah, J. K., Korngut, L., Dykeman, J., Day, L., Pringsheim, T., & Jette, N. (2014) · Neuromuscular Disorders · doi:10.1016/j.nmd.2014.03.008 · Cited by 490
Self-citationGlucocorticoid corticosteroids for Duchenne muscular dystrophy
Manzur, A. Y., Kuntzer, T., Pike, M., & Swan, A. V. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub3 · Cited by 437
The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy
McDonald, C. M., Henricson, E. K., Han, J. J., Abresch, R. T., Nicorici, A., Elfring, G. L., Atkinson, L., Reha, A., Hirawat, S., & Miller, L. L. (2010) · Muscle & Nerve · doi:10.1002/mus.21544 · Cited by 397
Self-citationMcdonald, C. M., Henricson, E. K., Abresch, R. T., Florence, J. M., Eagle, M., Gappmaier, E., Glanzman, A. M., PTC124‐GD‐007‐DMD Study Group, Spiegel, R., Barth, J., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.23902 · Cited by 303
Self-citationAdvances in human proteomics at high scale with the SOMAscan proteomics platform
Gold, L., Walker, J. J., Wilcox, S. K., & Williams, S. (2012) · New Biotechnology · doi:10.1016/j.nbt.2011.11.016 · Cited by 261
Self-citationDavies, D. R., Gelinas, A. D., Zhang, C., Rohloff, J. C., Carter, J. D., O’Connell, D., Waugh, S. M., Wolk, S. K., Mayfield, W. S., Burgin, A. B., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213933109 · Cited by 256
Self-citationMyostatin propeptide‐mediated amelioration of dystrophic pathophysiology
Bogdanovich, S., Perkins, K. J., Krag, T. O. B., Whittemore, L.-A., & Khurana, T. S. (2005) · The FASEB Journal · doi:10.1096/fj.04-2796com · Cited by 242
Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches
Fairclough, R. J., Wood, M. J., & Davies, K. E. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3460 · Cited by 229
Henricson, E. K., Abresch, R. T., Cnaan, A., Hu, F., Duong, T., Arrieta, A., Han, J., Escolar, D. M., Florence, J. M., Clemens, P. R., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.23808 · Cited by 208
Self-citationAtaluren as an Agent for Therapeutic Nonsense Suppression
Peltz, S. W., Morsy, M., Welch, E. M., & Jacobson, A. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-120611-144851 · Cited by 193
Heier, C. R., Damsker, J. M., Yu, Q., Dillingham, B. C., Huynh, T., Van der Meulen, J. H., Sali, A., Miller, B. K., Phadke, A., Scheffer, L., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302621 · Cited by 192
Self-citationMcDonald, C. M., Henricson, E. K., Abresch, R. T., Han, J. J., Escolar, D. M., Florence, J. M., Duong, T., Arrieta, A., Clemens, P. R., Hoffman, E. P., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.23807 · Cited by 183
Self-citationQiao, C., Li, J., Jiang, J., Zhu, X., Wang, B., Li, J., & Xiao, X. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.159 · Cited by 175
Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders
Smith, R. C., & Lin, B. K. (2013) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000013 · Cited by 170
Gupta, S., Hirota, M., Waugh, S. M., Murakami, I., Suzuki, T., Muraguchi, M., Shibamori, M., Ishikawa, Y., Jarvis, T. C., Carter, J. D., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.532580 · Cited by 151
Hathout, Y., Marathi, R., Rayavarapu, S., Zhang, A., Brown, K. J., Seol, H., Gordish‐Dressman, H., Çırak, S., Bello, L., Nagaraju, K., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu366 · Cited by 123
Self-citationAyoglu, B., Chaouch, A., Lochmüller, H., Politano, L., Bertini, E., Spitali, P., Hiller, M., Niks, E. H., Gualandi, F., Pontén, F., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201303724 · Cited by 122
Crystal Structure of Interleukin-6 in Complex with a Modified Nucleic Acid Ligand
Gelinas, A. D., Davies, D. R., Edwards, T. E., Rohloff, J. C., Carter, J. D., Zhang, C., Gupta, S., Ishikawa, Y., Hirota, M., Nakaishi, Y., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.532697 · Cited by 109
Regulation of GDF-11 and myostatin activity by GASP-1 and GASP-2
Lee, Y., & Lee, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309907110 · Cited by 105
Corticosteroids in Duchenne Muscular Dystrophy: A Reappraisal
Wong, B. L. Y., & Christopher, C. (2002) · Journal of Child Neurology · doi:10.1177/088307380201700306 · Cited by 85
Therapeutic advances in muscular dystrophy
Leung, D. G., & Wagner, K. R. (2013) · Annals of Neurology · doi:10.1002/ana.23989 · Cited by 84
New developments in the use of gene therapy to treat Duchenne muscular dystrophy
Jarmin, S., Kymäläinen, H., Popplewell, L. J., & Dickson, G. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.866087 · Cited by 74
The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.
McAdam, L. C., Mayo, A. L., Alman, B. A., & Biggar, W. D. (2012) · PubMed Central · Cited by 73
Novel Approaches to Corticosteroid Treatment in Duchenne Muscular Dystrophy
Hoffman, E. P., Reeves, E. K. M., Damsker, J. M., Nagaraju, K., McCall, J. M., Connor, E. M., & Bushby, K. (2012) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2012.08.003 · Cited by 72
Self-citationSystemic Myostatin Inhibition via Liver-Targeted Gene Transfer in Normal and Dystrophic Mice
Morine, K., Bish, L. T., Pendrak, K., Sleeper, M. M., Barton, E. R., & Sweeney, H. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009176 · Cited by 64
Self-citationPhospholipase A2 activity in dystrophinopathies
Lindahl, M., Backman, E. J., Henriksson, K. G., Gorospe, J. R. M., & Hoffman, E. P. (1995) · Neuromuscular Disorders · doi:10.1016/0960-8966(94)00045-b · Cited by 53
Self-citationGDNF increases the survival of developing oculomotor neurons through a target-derived mechanism
Chen, J., Butowt, R., Rind, H. B., & von Bartheld, C. S. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00098-8 · Cited by 34
Kim, J., Choi, J. Y., Park, S., Yang, S. H., Park, J. A., Shin, K., Lee, E., Kawachi, H., Kohsaka, H., & Song, Y. W. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4583 · Cited by 34
Cited by
Connecting genetic risk to disease end points through the human blood plasma proteome
Suhre, K., Arnold, M., Bhagwat, A. M., Cotton, R. J., Engelke, R., Raffler, J., Sarwath, H., Thareja, G., Wahl, A., DeLisle, R. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14357 · Cited by 800
Self-citationCo-regulatory networks of human serum proteins link genetics to disease
Emilsson, V., Ilkov, M., Lamb, J. R., Finkel, N., Gudmundsson, E. F., Pitts, R., Hoover, H., Gudmundsdottir, V., Horman, S. R., Aspelund, T., et al. (2018) · Science · doi:10.1126/science.aaq1327 · Cited by 680
Aptamers Chemistry: Chemical Modifications and Conjugation Strategies
Odeh, F., Nsairat, H., Alshaer, W., Ismail, M. A., Esawi, E., Qaqish, B., Bawab, A. A., & Ismail, S. I. (2019) · Molecules · doi:10.3390/molecules25010003 · Cited by 415
Röthlisberger, P., & Hollenstein, M. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.007 · Cited by 413
Kuo, C.-H. S., Pavlidis, S., Loza, M., Baribaud, F., Rowe, A., Pandis, I., Sousa, A., Corfield, J., Djukanovic, R., Lutter, R., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02135-2016 · Cited by 369
Metadata
- Authors
- Hathout, Y., Brody, E., Clemens, P. R., Cripe, L., DeLisle, R. K., Furlong, P., Gordish-Dressman, H., Hache, L., Henricson, E., Hoffman, E. P., Kobayashi, Y. M., Lorts, A., Mah, J. K., McDonald, C., Mehler, B., Nelson, S., Nikrad, M., Singer, B., Steele, F., Sterling, D., Sweeney, H. L., Williams, S., & Gold, L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2015-05-26
- Volume
- 112
- Issue
- 23
- Pages
- 7153-7158
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1573786554
- Cited by
- 290
- References
- 45
- FWCI
- 12.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.